GlassScriptPhysician profile
Gordon A Lang
NPI 1013380591
$2,874.53
in general payments reported to CMS, 2019-2025
28 companies · $589 in 2025
The $589 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,361 · 2022: $160 · 2023: $94.39 · 2024: $670 · 2025: $589.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,354.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,353.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| C. R. Bard, INC. & Subsidiaries | $624.35 | 2024-2025 | Bard Urinary Drainage Bag, Magic3 Go Intermittent Urinary Catheter |
| Boston Scientific Corporation | $426.19 | 2021-2025 | Ams 700 |
| Becton, Dickinson and Company | $264.17 | 2024 | Bard Urinary Drainage Bag |
| Kerecis Limited | $175.60 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Allergan, INC. | $132.56 | 2021 | |
| Janssen Biotech, INC. | $120.74 | 2021 | |
| Procept Biorobotics Corporation | $108.96 | 2021-2023 | Aquabeam Robotic System |
| Clarus Therapeutics INC. | $101.55 | 2021 | |
| Myriad Genetic Laboratories, INC. | $98.42 | 2021 | |
| Acerus Pharmaceuticals Corporation | $72.56 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $70.45 | 2021 | |
| Teleflex LLC | $67.41 | 2021-2022 | |
| Astellas Pharma US INC | $66.28 | 2021 | |
| Pfizer INC. | $60.16 | 2021 | |
| Merck Sharp & Dohme LLC | $57.70 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $56.56 | 2021 | |
| Blue Earth Diagnostics | $50.53 | 2021 | |
| Abbvie INC. | $44.11 | 2021 | |
| Endo Pharmaceuticals INC. | $40.99 | 2021 | |
| Amgen INC. | $40.26 | 2021 | |
| Antares Pharma, INC. | $38.84 | 2021 | |
| Convatec INC. | $33.56 | 2021 | |
| Urovant Sciences INC | $30.80 | 2021 | |
| Coloplast Corp | $30.28 | 2021 | |
| 180 Medical, INC. | $22.88 | 2021 | |
| Urogen Pharma, INC. | $20.00 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.52 | 2021 | |
| Travere Therapeutics, INC. | $1.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gordon Lang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.